QT Imaging Seeks Growth Amid Reimbursement Push, TAM Targets $3.8B by 2030

QT Imaging Holdings, Inc. (QTI) presented a growth strategy centered on reimbursement expansion and scaling its Breast Acoustic CT technology at the IAccess Alpha Virtual Best Ideas Fall Investment Conference in September 2026. The company aims to nearly double its 2025 revenue to approximately $39 million in 2026, driven by a 286% year-over-year increase to $18.9 million in 2025 and a first-half 2026 revenue of $14 million—an 116% rise from the same period in 2025. Revenue per scanner has climbed from $407,000 in 2024 to an estimated $488,000 in 2026, reflecting improved adoption and pricing power. Capital raises in 2025 and early 2026, including a $10 million public offering and a $10.1 million loan extension, have bolstered its liquidity, with cash and restricted cash totaling about $14.2 million as of August 2026. Despite a 57% year-to-date decline, QTI’s stock traded near its 52-week low of $2.51 on September 15, 2026, underscoring investor skepticism amid rapid revenue growth and regulatory hurdles. The company’s total addressable market (TAM) is projected to reach $2.5 billion by 2026, with the reimbursed segment accounting for roughly $1.7 billion, and expand to $3.8 billion by 2030, including $2.6 billion in reimbursed revenue. A key milestone is the introduction of a dedicated Category III CPT code for Breast Acoustic CT, effective January 1, 2027, following AMA approval in July 2026. Current reimbursement rates remain modest at about $200 per scan, though out-of-pocket costs at imaging centers range from $500 to $550. The technology, FDA-cleared and non-invasive, has been used on over 12,000 women, with repeatability studies showing less than 1% variability in core tissue biomarkers. QT Imaging has expanded its footprint with a new $22,000-square-foot headquarters and manufacturing facility in Petaluma, California, reducing real estate costs by about 55%. Regulatory approvals have extended to Saudi Arabia, the United Arab Emirates, and Israel, while distributors include NXC Imaging (U.S.), Gulf Medical (Saudi Arabia), and Al Naghi Medical (UAE). Clinical partnerships with institutions like the Mayo Clinic and Harvard University support its feasibility studies, including a Mayo Clinic trial comparing QTscan with MRI in high-risk patients. Chief Financial Officer Jay Jennings emphasized the platform’s value proposition, framing hardware as a gateway and software as the core driver of long-term growth. The company’s strategy hinges on improving physician adoption, patient experience, and reimbursement alignment, despite a market capitalization of $38 million and a current ratio of 3.1, signaling cautious optimism amid regulatory and reimbursement challenges.